Qilian International Holding Group Limited (QLI) Research

Qilian International Holding Group Limited (QLI), founded in 2019 and headquartered in Jiuquan, People's Republic of China, focuses on the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMDs), and a variety of other products. The company's diverse offerings include licorice-derived products such as Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, supplied to pharmaceutical companies for manufacturing traditional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient for producing compound licorice oral solutions. QLI also produces Qilian Shan oxytetracycline tablets, used to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and humans, alongside Qilian Shan oxytetracycline APIs for other pharmaceutical manufacturers. Its TCMD line features Ahan antibacterial paste, designed for addressing stubborn chronic skin ailments. Furthermore, the company provides heparin sodium preparations to pharmaceutical firms for developing medications related to cardiovascular diseases, cerebrovascular conditions, and hemodialysis. Beyond the medical sector, Qilian International offers Zhu Xiaochang natural sausage casings for culinary applications. In agriculture, it produces Xiongguan organic fertilizers, formulated to improve crop yield, enhance soil chemical properties, and reduce compaction, as well as Xiongguan organic-inorganic compound fertilizers to stimulate plant growth.

Open Qilian International Holding Group Limited (QLI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.